Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00345618
Other study ID # EFC6034
Secondary ID EudraCT:2006-001
Status Completed
Phase Phase 3
First received June 27, 2006
Last updated December 6, 2013
Start date June 2006
Est. completion date October 2010

Study information

Verified date December 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

Objectives are to evaluate whether idrabiotaparinux (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic deep venous thrombosis (DVT) and to assess its safety (bleedings) versus warfarin.


Description:

Treatment with a therapeutic dose of any low molecular weight heparin (LMWH) or unfractioned heparin (UFH) or fondaparinux is allowed only within the 36 hours immediately preceding randomization. Randomization is performed as soon as the diagnosis of PE (and DVT if concomitant suspected symptomatic DVT) is confirmed.

Allocation to treatment is done centrally by Interactive Voice Response System (IVRS) and stratified by (1) center, (2) intended treatment duration, ie, 3 months or 6 months. At randomization, the planned duration of treatment (3 or 6 months) is prespecified by the Investigator and determined on the assessment of risk of VTE recurrence. Participants are randomized to either idrabiotaparinux + placebo of warfarin, or warfarin + placebo of idrabiotaparinux, with an initial treatment of at least 5 days with enoxaparin in both treatment groups.

Participants in the 3-month stratum have an additional 13-week observational period after cessation of study treatment. Participants in the 6-month stratum have a 13-week up to 26-week observational period.


Recruitment information / eligibility

Status Completed
Enrollment 3202
Est. completion date October 2010
Est. primary completion date October 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis

Exclusion Criteria:

- End stage renal failure, hepatic failure, uncontrolled hypertension;

- Active bleeding or high risk for bleeding;

- Pregnancy or childbearing potential without proper contraceptive measures, threatened abortion.

- Breastfeeding.

- Known allergy to idraparinux or idrabiotaparinux, avidin or egg proteins;

- hypersensitivity to warfarin, enoxaparin, heparin or pork product; or any other contraindication listed in the labelling of warfarin or enoxaparin;

- Indication of prolonged anticoagulation therapy for other reason than PE;

- Life expectancy < 6 months;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Idrabiotaparinux
0.5 mL pre-filled syringe for 3.0 mg Subcutaneous injection
Warfarin
Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month) Oral administration
Placebo (for idrabiotaparinux)
0.5 mL pre-filled syringe Subcutaneous injection
Avidin
100 mg in 10 mg/mL solution Intravenous infusion for 30 minutes
Placebo (for warfarin)
Warfarin matching capsules Oral administration
Enoxaparin
Prefilled syringes as locally registered Subcutaneous injection
Placebo (for avidin)
Avidin matching powder in 10 mg/mL solution Intravenous infusion for 30 minutes

Locations

Country Name City State
Argentina Sanofi-Aventis Administrative Office Buenos Aires
Australia sanofi-aventis Australia & New Zealand administrative office Macquarie Park New South Wales
Austria Sanofi-Aventis Administrative Office Wien
Belarus Sanofi-Aventis Administrative Office Minsk
Belgium Sanofi-Aventis Administrative Office Diegem
Brazil Sanofi-Aventis Administrative Office Sao Paulo
Bulgaria Sanofi-Aventis Administrative Office Sofia
Canada Sanofi-Aventis Administrative Office Laval
Chile Sanofi-Aventis Administrative Office Santiago
China Sanofi-Aventis Administrative Office Shangai
Colombia Sanofi-Aventis Administrative Office Santafe de Bogota
Croatia Sanofi-Aventis Administrative Office Zagreb
Czech Republic Sanofi-Aventis Administrative Office Praha
Denmark Sanofi-Aventis Administrative Office Horsholm
Egypt Sanofi-Aventis Administrative Office Cairo
Estonia Sanofi-Aventis Administrative Office Tallinn
France Sanofi-Aventis Administrative Office Paris
Greece Sanofi-Aventis Administrative Office Athens
India Sanofi-Aventis Administrative Office Mumbai
Israel Sanofi-Aventis Administrative Office Natanya
Italy Sanofi-Aventis Administrative Office Milano
Mexico Sanofi-Aventis Administrative Office Mexico
Netherlands Sanofi-Aventis Administrative Office Gouda
Norway Sanofi-Aventis Administrative Office Lysaker
Peru Sanofi-Aventis Administrative Office Lima
Philippines Sanofi-Aventis Administrative Office Makati City
Poland Sanofi-Aventis Administrative Office Warszawa
Portugal Sanofi-Aventis Administrative Office Porto Salvo
Puerto Rico Sanofi-Aventis Administraive Office Puerto Rico
Russian Federation Sanofi-Aventis Admnistrative Office Moscow
Slovakia Sanofi-Aventis Administrative Office Brastislava
South Africa Sanofi-Aventis Administrative Office Midrand
Spain Sanofi-Aventis Administrative Office Barcelona
Sweden Sanofi-Aventis Administrative Office Bromma
Turkey Sanofi-Aventis Administrative Office Istanbul
Ukraine Sanofi-Aventis Administrative Office Kiev
United Kingdom Sanofi-Aventis Administrative Office Guildford Surrey
United States Sanofi-Aventis Administrative Office Bridgewater New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belarus,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Croatia,  Czech Republic,  Denmark,  Egypt,  Estonia,  France,  Greece,  India,  Israel,  Italy,  Mexico,  Netherlands,  Norway,  Peru,  Philippines,  Poland,  Portugal,  Puerto Rico,  Russian Federation,  Slovakia,  South Africa,  Spain,  Sweden,  Turkey,  Ukraine,  United Kingdom, 

References & Publications (1)

Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE; Cassiopea Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-d — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence of symptomatic, fatal or not, VTE (PE or DVT) as confirmed by a Central Independent Adjudication Committee (CIAC) 3 months No
Secondary Recurrence of symptomatic, fatal or not, VTE (PE or DVT) as confirmed by a Central Independent Adjudication Committee (CIAC) 6 months No
Secondary Incidence of any clinically relevant bleeding as classified by the CIAC (ie, major bleeding and other clinically relevant non major bleeding) 3 months, 6 months and 3- to 6-month post-treatment follow-up Yes
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT05426564 - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Not yet recruiting NCT05830916 - Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
Recruiting NCT02972385 - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02439190 - CV004-007 Thrombosis Chamber Study Phase 1
Completed NCT02526628 - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed NCT02341638 - Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects Phase 1
Completed NCT01855516 - Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin N/A
Unknown status NCT00983112 - Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery Phase 4
Completed NCT00412464 - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Phase 1
Completed NCT00479362 - Anticoagulant Therapy During Pacemaker Implantation Phase 4
Completed NCT00346424 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters Phase 3
Completed NCT00143715 - Oral Vitamin K for Warfarin Associated Coagulopathy Phase 3
Terminated NCT00303420 - Alteplase for Blood Flow Restoration in Hemodialysis Catheters Phase 4
Completed NCT00039858 - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Phase 4
Completed NCT00007410 - Genetic Architecture of Plasma T-PA and PAI-1 N/A
Completed NCT00000538 - Dietary Effects on Lipoproteins and Thrombogenic Activity Phase 3
Completed NCT00005436 - Lupus Cohort--Thrombotic Events and Coronary Artery Disease N/A